New drug combo shows promise for leukemia patients
NCT ID NCT03447808
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a combination of two drugs, daratumumab and ibrutinib, in 15 people with untreated chronic lymphocytic leukemia (CLL) who needed therapy. The goal was to see if the combination is safe and how well it works at controlling the disease. Participants received both drugs, and researchers monitored side effects and cancer response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Smartwatches track hidden heart risk in blood cancer patients
- Triple-drug attack aims to wipe out hidden leukemia cells
- Engineered immune cells take aim at stubborn blood cancers
- Can a tailored exercise and diet plan beat cancer fatigue?
- Triple-Drug cocktail aims to tame untreated CLL